These Analysts Slash Their Forecasts On F5 Following Q4 Results

F5 Inc. (FFIV) reported strong fourth-quarter results, surpassing analyst estimates with EPS of $4.39 and revenue of $810.09 million, driven by 8% year-over-year revenue growth and significant product segment expansion. However, the company issued a weaker-than-expected first-quarter outlook, projecting EPS and sales below consensus estimates, which led to a 10.1% decline in its shares during pre-market trading. Following the announcement, several analysts, including Morgan Stanley and Piper Sandler, lowered their price targets on F5 while largely maintaining their existing ratings.

Analysis

F5 Inc. (FFIV) reported robust fourth-quarter results, surpassing analyst estimates with an EPS of $4.39 and sales of $810.09 million, driven by 8% year-over-year revenue growth and 16% product revenue increase. Despite strong full-year performance, including 10% revenue growth, the company issued a significantly weaker first-quarter outlook. It projected adjusted Q1 EPS of $3.35-$3.85 against a $4.03 analyst estimate and sales of $730 million-$780 million versus a $791.412 million consensus.

This conservative forward guidance immediately triggered a 10.1% decline in FFIV shares during pre-market trading to $261.00. Several prominent analysts, including Morgan Stanley and Piper Sandler, subsequently lowered their price targets, with BofA Securities cutting its target from $260 to $250 and maintaining an Underperform rating. The collective reduction in price targets reflects a cautious stance on F5's near-term prospects.

The divergence between strong historical performance and conservative forward guidance suggests potential near-term headwinds or a more cautious management outlook. This creates uncertainty regarding the sustainability of F5's growth trajectory, particularly in its key product segment. The market's negative reaction and analyst adjustments underscore concerns about future revenue and earnings deceleration.

Key Decisions for Investors

• Closely monitor F5's Q1 performance for signs of stabilization or further deceleration, particularly in product revenue growth, given the weak guidance
• Consider the implications of the lowered analyst price targets, especially BofA's $250 target which is below the pre-market trading price, indicating potential further downside risk
• Evaluate whether the current 10.1% share price decline fully discounts the weaker Q1 outlook, or if continued uncertainty warrants a cautious approach to new or existing positions